Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Metabolic Syndrome, Obese, Sedentary
Interventions: Statin, Exercise only, Statins + Exercise; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 25 Years to 59 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions: Bottarga, Comparator; Other
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sommerville, Massachusetts

Conditions: Diabetes, Metabolic Syndrome
Interventions: Cardiac CT, Usual medical care; Diagnostic Test · Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Orange, California

Conditions: Cholesterol, LDL, Cholesterol, HDL, Research Subjects
Interventions: Low-fat ground beef, High-fat ground beef; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: College Station, Texas

Conditions: HIV-1-infection, Hypertension
Interventions: EXTRA-CVD Virtual Care; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Durham, North Carolina • Cleveland, Ohio

Conditions: Healthy Volunteers, Statins, Immune Modulation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cholesterol
Interventions: Standard whey, Hydrolyzed whey; Dietary Supplement
Lead sponsor: Medinutra LLC; Other
Eligibility: 21 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, Atorvastatin, Atorvastatin Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more

Conditions: HDL Cholesterol
Interventions: Not listed
Lead sponsor: KineMed; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of North Carolina; Other
Eligibility: 20 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions: Placebo, Colesevelam; Drug
Lead sponsor: Radiant Research; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo, Background Statin Therapy; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 134
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more

Conditions: Type 2 Diabetes, African American, Cholesterol, Lipoprotein, Apolipoprotein
Interventions: Not listed
Lead sponsor: Mercer University; Other
Eligibility: 18 Years to 79 Years · Male only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Metabolic Syndrome
Interventions: ELM Group, ELM Classes, ELM Individual; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperlipidemia
Interventions: Placebo, MBX-8025, Atorvastatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more

Conditions: Scleroderma
Interventions: atorvastatin, Placebo; Drug
Lead sponsor: Robyn T. Domsic, MD, MPH; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Hyperlipidemia
Interventions: Atorvastatin; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 10 Years to 23 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 11
States / cities: Aurora, Colorado • Miami, Florida • Tampa, Florida + 7 more

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more

Conditions: Coronary Artery Disease, Atherosclerosis
Interventions: ACP-501; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions: Colesevelam, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Medical Conditions to be Studied, Dyslipidemia, ASCVD Management
Interventions: Not listed
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 5,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 118
States / cities: Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 101 more

Search by objective public record fields.

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Exercise, Statins, and the Metabolic Syndrome

Atherosclerosis in the Coronary and Carotid Arteries

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome

Impact of Beef's Unique Food Matrix on Human Health

Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV

Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol

Whey Protein Comparisons for Blood Lipid Effects

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Effect of Niaspan on Cholesterol in Men

Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States